National Laboratories Excellence program (under the National Tumor Biology Laboratory
Project(NLP-17)
(TKP2020-NKA-26)
(2020.-1.1.6.-Jövő)
Cutaneous melanoma is the third most common type of skin cancer in the world. The
incidence of melanoma is increasing in most countries, however, mortality seems to
be slowly decreasing. The treatment of advanced cutaneous melanoma changed radically
since 2011. The new therapeutic modalities, such as immuno- and targeted therapies
give a chance to successfully reach more prolonged progression-free survival (PFS)
and overall survival (OS) in patients with metastatic melanoma. Despite the great
therapeutic benefit, most patients eventually develop resistance to these therapies,
and the disease will progress. In some cases oligoprogression develops. In those cases
local therapy, such as stereotactic radiotherapy can make it possible to continue
the previously applied effective medical treatment for the benefit of patients. In
our study of a total of 30 patients—20 of them received pre-treatment with systemic
medical therapy—received stereotactic radiotherapy using various systems, in the National
Institute of Oncology, Hungary, Budapest. We managed to prolong the systemic therapy
for 12.5 months median period with the assistance of CyberKnife technique. Therapy
related adverse events were mostly tolerable with only 3% of Grade 3 toxicity. We
concluded that stereotactic radiotherapy and stereotactic radiosurgery, are safe,
and effective therapeutic modalities for regional tumor control in cases of oligoprogression.
